Old money out, new money in: the company is redirecting its own capital away from what it has always done and into a spe
The model's full reasoning — Q1 2017 call → NOWe need to determine if the company is redirecting its own capital and operating resources from a historical activity into a newer identifiable effort, with something getting less, and management treating it as defining. The transcript is from Ionis Pharmaceuticals. They have multiple programs. Key points: They have a strong financial position, with revenue from SPINZARA royalties, R&D revenue from partnerships. They mention forming Akcea as a subsidiary to develop and commercialize cardiometabolic drugs. They are planning an IPO for Akcea. They talk about "transition to a multiproduct profitable organization." They mention that they are able to retain larger portion of commercial value by developing drugs longer and creating subsidiaries like Akcea. They say "We're now able to retain a larger portion of the commercial value from our drugs in a number of ways, including develop our -- developing our drugs longer before partnering and creating subsidiaries like Akcea to develop and commercialize additional drugs in our pipeline." So they are creating Akcea as a separate company to focus on cardiometabolic drugs. They are investing in Akcea's infrastructure, building a commercial team, etc. They are also planning to launch volanesorsen. They have a collaboration with Novartis for two of Akcea's drugs. They are also advancing other programs. Is there a redirection of resources? They are forming Akcea, which is a separate entity, but Ionis is still the parent. They are putting resources into Akcea. But is something getting less? They mention that R&D expenses will be lower as they concluded costly Phase III programs. They also say "we're forecasting an increase in our SG&A expenses as Akcea continues to prepare to launch volanesorsen in 2018. And we expect our R&D expenses to be lower as we concluded our costly Phase III program." So they are shifting from R&D to SG&A for commercialization? But that's not necessarily a redirection from a historical activity to a new one. They are also advancing many other programs. They say "Because of the efficiency of our technology, even with climbing R&D expenses this year, we will continue to advance our earlier-stage drugs and add new drugs to our pipeline." So they are still investing in R&D across the board.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| TWLO | Twilio Inc. | Q4 2022 | 2023-02-15 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| CTHR | Charles & Colvard, Ltd. | Q1 2023 | 2022-11-06 | F |
| AWRE | Aware, Inc. | Q3 2022 | 2022-10-30 | F |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| LOB | Live Oak Bancshares, Inc. | Q3 2018 | 2018-10-25 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| HPE | Hewlett Packard Enterprise Company | Q2 2018 | 2018-05-22 | B+ |
| SCVL | Shoe Carnival, Inc. | Q4 2017 | 2018-03-27 | C+ |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DHX | DHI Group, Inc. | Q2 2017 | 2017-07-28 | D |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| DUK | Duke Energy Corporation | Q2 2016 | 2016-08-04 | B |
| INGR | Ingredion Incorporated | Q1 2016 | 2016-05-01 | B+ |
DUK · Q2 2016 → YESThe question is about whether Duke Energy is redirecting its own capital and operating resources from historical uses to a newer effort, with all three conditions met. YES The transcript shows Duke Energy's management describing a clear portfolio transition: exiting the Latin American generation business (historical international operations) while redirecting resources toward building a domestic energy infrastructure business focused on natural gas infrastructure, renewables, and grid modernization. This is framed as a strategic shift to a lower-carbon future, with a 30 billion dollar capital plan already in motion for these initiatives. Management explicitly ties the redirection to defining the company's future composition, noting that after these transactions, the portfolio will emphasize low-risk domestic infrastructure rather than the prior mix of international and coal-heavy assets.
PRPH · Q1 2023 → YESThe question is about whether management describes a redirection of the company's own capital and operating resources from historical activities to a newer effort. YES The transcript shows management describing a clear redirection: COVID testing (the historical windfall) is winding down naturally as PHE ends, freeing resources, while incremental capital, people, and attention are flowing into newer efforts like manufacturing capacity, Nebula Genomics, esophageal cancer test, and Linebacker. Ted Karkus explicitly states 2024 is a "transition year" focused on building underlying company value rather than earnings, with COVID revenues expected to weaken. They are converting lab infrastructure from COVID to full clinical and genomic testing, hiring for new assets, and investing in R&D and validations—all funded from prior cash generation, not new external capital.
IRT · Q2 2018 → YESThe question is about whether management describes a redirection of the company's own capital and operating resources to something new, away from historical uses, treating this as defining the company...YES The transcript shows management describing a clear redirection of capital: proceeds from selling five non-core communities are being recycled to acquire assets in preferred scalable markets (Atlanta, Orlando, Tampa, Carolinas), with two acquisitions already completed post-quarter. This is framed as accelerating portfolio concentration in markets with stronger fundamentals, while the value-add program on existing properties is positioned as a key driver of incremental NOI and NAV. Current results still reflect the pre-reallocation portfolio, and management explicitly ties the shift to defining future scale and composition.